<DOC>
	<DOCNO>NCT00361179</DOCNO>
	<brief_summary>Chronic hepatitis C may relapse simple chronic hepatitis C patient initially obtain sustain virologic response . Although HCV SVR could maintain around 90 % , remain 10 % patient may develop hepatitis C relapse follow-up . Therefore , important follow long-term patient dual chronic hepatitis B C. From another aspect , treatment chronic hepatitis B , virologic serologic response may also durable . Alternatively , previous study suggest therapeutic efficacy might see study period , incremental response might occur long-term follow-up . Therefore also important clarify long-term outcome treatment dually infected population . Evaluation long term effect treatment peginterferon alfa-2a plus ribavirin patient chronic hepatitis C/ hepatitis B co-Infection chronic hepatitis C original study ML17862 important . This present protocol thus assess whether HCV SVR sustain assess durability HBV virologic serologic response incremental response 5-year follow-up period , include six month end therapy original study additional 4 half year project ( 5 year overall follow-up end treatment ) . Specifically , wish ass ( 1 ) sustain virologic response ( SVR ) HCV population , ( 2 ) incidence HBsAg loss HBsAg seroconversion ( HBsAg loss appearance anti-HBs ) dually infected population , ( 3 ) ALT normalization flare off-treatment population , ( 4 ) reduction HCV RNA original baseline level two patient population , ( 5 ) reduction serum HBV DNA off-treatment dually infected population .</brief_summary>
	<brief_title>Long Term Effects Peginterferon Alfa-2a Plus Ribavirin Chronic Hepatitis C/B Co-Infection Chronic Hepatitis C</brief_title>
	<detailed_description>Pegylated IFNs ( PEG-IFN alfa-2a , PEGASYSÂ® ) show possess superior efficacy convenience conventional IFNs , either alone combination RBV patient chronic hepatitis C [ Zeuzem et al , 2000 ; Heathcote et al , 2000 ; Fried et al , 2002 ; Hadziyannis et al , EASL 2002 ] . For patient chronic hepatitis B , pilot study also reveal biochemical virologic response well HBeAg-positive patient receive pegylated IFN receive conventional IFN [ 24-week post-treatment combine virologic , HBeAg loss , ALT normalization rate : 28 % vs. 12 % ; Lai et al , APSAL 2002 ] . The efficacy use 24-week combination therapy sustain clearance serum HCV RNA equivalent use 48-week combination therapy patient HCV genotype non-1 [ Hadziyannis et al , EASL 2002 ] . A 48-week course pegylated IFN RBV combination therapy , contrast , show yield well efficacy sustained clearance serum HCV RNA patient HCV genotype 1 24-week combination therapy western country [ SVR : 40~51 % vs. 29~41 % , Table 1 , Hadziyannis et al , EASL 2002 ; Poynard et al , 1998 ] . Based finding , NIH Consensus Statement suggest patient genotype 1 need 48 week combination treatment standard dose RBV [ NIH 2002 ] . Previous study reveal 12-week RBV therapy effective patient chronic hepatitis B [ Kakumu et al , 1993 ] . Therefore , proposal , treatment duration 24 week HCV genotype 2/3 , 48 week HCV genotype 1 , patient monoinfected chronic hepatitis C dual chronic hepatitis C B . Increased RBV dosage consider contributory factor well efficacy previous study . Recent study suggest use RBV 800 mg daily adequate treatment HCV genotype non-1 standard dosage RBV require treatment HCV genotype 1 [ NIH 2002 ] . We follow recommendation use RBV 800 mg daily HCV genotype non-1 , dually infected patient monoinfected chronic hepatitis C patient . RBV 1000-1200 mg daily use HCV genotype 1 accord body weight patient , dually infected patient monoinfected chronic hepatitis C patient . Previous study suggest chronic hepatitis C may relapse simple chronic hepatitis C patient initially obtain sustain virologic response 6 month end treatment [ Chemello et al , 1996 ; Marcellin et al , 1997 ] . Although HCV SVR could maintain around 90 % , remain 10 % patient may develop hepatitis C relapse follow-up . Chemello et al follow 107 patient chronic hepatitis C maintain normal aminotransferase level long 12 month interferon-alpha therapy [ Chemello et al , 1996 ] . Hepatitis C virus RNA detect 27 ( 25 % ) patient sustain biochemical response ; 80 ( 75 % ) patient negative HCV RNA . Patients positive HCV RNA older ( P &lt; 0.001 ) , receive small interferon-alpha dose ( P = 0.02 ) , frequently infect HCV genotype 2 ( P &lt; 0.01 ) . Liver histologic finding active 57 % patient positive HCV RNA , despite normal alanine aminotransferase level , compare 12 % patient negative HCV RNA ( P = 0.01 ) . The estimated probability hepatitis relapse 4 year therapy 53 % viremic patient 0 % patient negative HCV RNA ( P &lt; 0.001 ) . Marcellin et al follow 80 patient chronic hepatitis C receive interferon-alpha therapy [ Marcellin et al , 1997 ] . The 80 patient follow-up 1 7.6 year ( mean +/- SD , 4.0 +/- 2.0 year ) interferon-alpha treatment . The follow-up period 1 , 2 , 3 , 4 , 5 , 6 , 6 year 11 , 13 , 14 , 18 , 10 , 12 , 2 patient , respectively , end therapy . During entire follow-up period , 93 % ( 95 % CI , 84 % 97 % ) patient persistently normal serum ALT level . Serum HCV RNA remain undetectable 96 % ( CI , 89 % 99 % ) patient . A comparison liver histologic finding 1 6.2 year interferon-alpha treatment show clear improvement 94 % ( CI , 83 % 99 % ) patient . In 62 % patient , last biopsy do show normal nearly normal histologic finding . Liver HCV RNA detectable treatment 13 patient test undetectable 1 5 year treatment 27 patient test . They thus conclude patient chronic hepatitis C persistently normal serum ALT level detectable serum HCV RNA 6 month interferon-alpha therapy , long-term sustain biochemical virologic response generally see . Similar finding note one report case dual chronic hepatitis B C [ Yalcin et al , 2003 ] . To note , dually infected patient reactivation hepatitis B accompany severe flare hepatitis activity treatment relapse hepatitis C end treatment . Therefore , important follow long-term patient dual chronic hepatitis B C. From another aspect , treatment chronic hepatitis B , virologic serologic response may also durable [ Liaw et al , 2005 ; Lok et al , 2004 ; Hadziyannis et al , 2003 ; Janssen et al , 2005 ] . Alternatively , previous study suggest therapeutic efficacy might see study period , incremental response might occur long-term follow-up learn previous experience use antiviral agent include interferon treatment chronic hepatitis B [ Saruc et al , 2003 ; Carreno et al , 2001 ] . Therefore also important clarify long-term outcome treatment dually infected population . This present protocol thus assess whether HCV SVR sustain assess durability HBV virologic serologic response incremental response 5-year follow-up period , include six month end therapy original study additional 4 half year project ( 5 year overall follow-up end treatment ) . Specifically , wish ass ( 1 ) sustain virologic response ( SVR ) HCV population , ( 2 ) incidence HBsAg loss HBsAg seroconversion ( HBsAg loss appearance anti-HBs ) dually infected population , ( 3 ) ALT normalization flare off-treatment population , ( 4 ) reduction HCV RNA original baseline level two patient population , ( 5 ) reduction serum HBV DNA off-treatment dually infected population .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients randomize , treat return follow ML17862 protocol eligible inclusion protocol Patients unwilling provide inform consent abide requirement study . Patients already initiate antiHCV HBV treatment , approve investigational since completion original protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>Observation</keyword>
	<keyword>Post-treatment</keyword>
</DOC>